Segesterone
Annovera (segesterone) is a small molecule pharmaceutical. Segesterone was first approved as Annovera on 2018-08-10.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Annovera
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ethinyl estradiol
+
Segesterone acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ANNOVERA | Mayne Group | N-209627 RX | 2018-08-10 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| annovera | New Drug Application | 2022-08-23 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J7294 | Segesterone acetate and ethinyl estradiol 0.15mg, 0.013mg per 24 hours; yearly vaginal system, each |
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | — | — | 5 | 3 | 2 | — | — | 10 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | 1 | — | — | — | 3 |
| Ovulation inhibition | D034445 | — | — | — | 2 | — | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Segesterone |
| INN | segesterone |
| Description | Segesterone (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), also known as 17α-hydroxy-16-methylene-19-norprogesterone or as 17α-deacetylnestorone, is a steroidal progestin of the 19-norprogesterone group that was never marketed. An acetate ester, segesterone acetate, better known as nestorone or elcometrine, is marketed for clinical use. Segesterone acetate produces segesterone as a metabolite.
|
| Classification | Small molecule |
| Drug class | progestins; steroids (androgens, anabolics); antiandrogens |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=C1C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]2(C)[C@@]1(O)C(C)=O |
Identifiers
| PDB | — |
| CAS-ID | 7690-08-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107778 |
| ChEBI ID | — |
| PubChem CID | 11823650 |
| DrugBank | — |
| UNII ID | 09Q5UV3747 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Annovera – TherapeuticsMD
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 334 documents
View more details
Safety
Black-box Warning
Black-box warning for: Annovera
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
138 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use